Last reviewed · How we verify
Lactobacillus salivarius HN6
Lactobacillus salivarius HN6 is a Biologic drug developed by Universidad Complutense de Madrid. It is currently in Phase 2 development.
At a glance
| Generic name | Lactobacillus salivarius HN6 |
|---|---|
| Sponsor | Universidad Complutense de Madrid |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lactobacillus salivarius HN6 CI brief — competitive landscape report
- Lactobacillus salivarius HN6 updates RSS · CI watch RSS
- Universidad Complutense de Madrid portfolio CI
Frequently asked questions about Lactobacillus salivarius HN6
What is Lactobacillus salivarius HN6?
Lactobacillus salivarius HN6 is a Biologic drug developed by Universidad Complutense de Madrid.
Who makes Lactobacillus salivarius HN6?
Lactobacillus salivarius HN6 is developed by Universidad Complutense de Madrid (see full Universidad Complutense de Madrid pipeline at /company/universidad-complutense-de-madrid).
What development phase is Lactobacillus salivarius HN6 in?
Lactobacillus salivarius HN6 is in Phase 2.